Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor.

Biotechnology

Renovacor

Renovacor's headquarters in Philadelphia, PA, United States

Magdalene Cook

Wendy DiCicco

Jiwen Zhang

Matt Killeen

Beth White

Marc Semigran

Richard Peluso

Jonas Grossman

Gregory F. Covino

Joan Lau

Gbola Amusa

Lee Sweeney

Edward J Benz

Arthur Feldman

Dennis McNamara

Thomas Needham

Douglas Mann

Joseph Glorioso III

Michael Bristow

The Scientific Advisory Team at Renovacor provides expert guidance on the development and strategic direction of AAV-based gene therapies targeting cardiovascular and CNS diseases caused by BAG3 gene variants. This team of highly skilled advisors collaborates closely with internal research and development teams to ensure that the scientific approaches taken are cutting-edge, feasible, and aligned with the latest advancements in the biotechnology field.

Scientific Advisory Team

The Directors team at Renovacor is responsible for overseeing various strategic aspects of the company's operations, including preclinical development, regulatory affairs, clinical strategy, and business development. They collaborate to guide the company’s efforts in developing AAV-based gene therapies for cardiovascular and CNS diseases, ensuring alignment with scientific and commercial goals.

Directors

This department provides strategic direction and oversight for the organization, ensuring alignment with its mission and goals.

Executive Leadership

This department oversees the technical operations and clinical development processes within the organization.

Technical Operations

The Leadership Team at Renovacor is responsible for setting the strategic direction and ensuring the operational execution of the company's mission to develop innovative gene therapies for cardiovascular and CNS diseases. This team, composed of executives with expertise in business, operations, regulatory affairs, technical development, and medical science, collaborates to drive research initiatives, oversee clinical development, and navigate regulatory pathways, ultimately positioning Renovacor for success in the biotechnology industry.

Renovacor

Org chart

Board & advisors

Teams

Scientific Advisory Team

Directors

Executive Leadership

Technical Operations

Leadership Team

Offices

Renovacor

Org chart

Board & advisors

Teams

Scientific Advisory Team

Directors

Executive Leadership

Technical Operations

Leadership Team

Offices

Related companies